SI
SI
discoversearch

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor.  We ask that you disable ad blocking while on Silicon Investor in the best interests of our community.  If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.
Biotech / Medical : TTPH, Tetraphase Pharmaceuticals
TTPH 2.200-3.5%Jul 28 5:00 PM EST
 Public ReplyPrvt ReplyMark as Last ReadFilePrevious 10Next 10PreviousNext  
To: HardToFind who wrote (33)9/12/2016 3:50:04 PM
From: gcrispin1 Recommendation

Recommended By
HardToFind

  Read Replies (1) of 80
 
"Do you consider it a knock on management..."

This was a forty dollar stock that is now selling for less than four dollars. It doesn't really matter what I think. It is what the market is telling you. The management team lost the confidence of the market. If you think about it, this company could be applying for an NDA right now. Instead they are repeating a phase 3 trial that will cost 30 million dollars. More importantly, they have extended the time of the cash burn.

You have to wonder if there will ever be a timely oral version of eravacycline.

That said, I have been a buyer at these levels as the stock is oversold. Tax loss selling will disappear, and the prospect of a second successful phase III trial will become clearer.
Report TOU ViolationShare This Post
 Public ReplyPrvt ReplyMark as Last ReadFilePrevious 10Next 10PreviousNext  

HomeMailHotSubjectMarksPeopleMarksKeepersSettings
Terms Of UseContact UsCopyright/IP PolicyPrivacy PolicyAbout UsFAQAdvertise on SI
© 2025 Knight Sac Media.  Data provided by Twelve Data, Alpha Vantage, and CityFALCON News